The “Red Devil” Chemotherapy: Who May Benefit From Anthracyclines in Early-Stage Breast Cancer?

Doxorubicin, also called Adriamycin, is a chemotherapy medicine that has been used to treat breast cancer for decades. Some people call it the “Red Devil” chemotherapy because of its bright red color and potential side effects. In this article, we’ll mostly refer to it by its medical name, doxorubicin, or as anthracycline chemotherapy.

For people diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer, the question is no longer simply: Do I need chemotherapy?

HR-positive means the cancer uses hormones like estrogen or progesterone to grow. HER2-negative means the cancer does not have high levels of the HER2 protein.

There may be a second question.

If I need chemotherapy, would I benefit from an anthracycline such as doxorubicin — or could another chemotherapy regimen offer similar protection without its added risks?

Emerging research suggests genomic testing with MammaPrint and BluePrint may help answer that question by looking more closely at the biology inside each person’s tumor.
While some patients with early-stage HR-positive, HER2-negative breast cancer may benefit from doxorubicin/anthracycline-containing chemotherapy, others may achieve similar outcomes with non-anthracycline treatment approaches. Genomic testing can help identify which patients are more likely to benefit from the addition of an anthracycline.

What Is the “Red Devil” Chemotherapy?

The nickname “Red Devil” most commonly refers to doxorubicin. The medication is bright red and is given intravenously.

Although this name can sound frightening, it does not tell you whether doxorubicin/anthracycline is right for you. It is a powerful and well-established chemotherapy medication that may provide meaningful benefit for certain breast cancers.

If you are new to this treatment, our full guide to Red Devil chemotherapy walks through what it is and what to expect.

Doxorubicin is part of a class of drugs called anthracyclines. It may be included in an AC-T chemotherapy regimen:

• A: Adriamycin, or doxorubicin
• C: Cyclophosphamide
• T: A taxane, such as paclitaxel or docetaxel

A commonly used non-anthracycline regimen for patients with HR-positive, HER2-negative breast cancer is TC, which usually combines docetaxel and cyclophosphamide.

Both regimens may be appropriate for early-stage breast cancer. The important question is which one is most likely to benefit the individual patient.

Why Isn’t Anthracycline Chemotherapy Given to Everyone?

Anthracyclines can be highly effective, but they also carry potential short-term and long-term risks.

Possible side effects include:

• Fatigue
• Hair loss
• Nausea and vomiting
• Mouth sores
• Lower blood cell counts
• Increased risk of infection
• Effects on heart function
• A rare risk of treatment-related blood cancers

Many of these are manageable, and knowing when they tend to arrive helps. Our guide to the chemotherapy 7-day rule explains the rhythm of a treatment cycle, and when hair grows back after chemotherapy answers the question almost everyone asks first.

Before treatment, doctors may test how well the heart is functioning. Additional monitoring may be recommended during or after chemotherapy.

The goal is not to avoid anthracyclines when they may substantially reduce the risk of recurrence.

It is to identify the patients most likely to benefit, while avoiding additional toxicity for those who may do equally well with a different regimen.

Two Important Chemotherapy Questions

When chemotherapy is being considered, patients and their oncology teams may need to answer two separate questions:

1. Is chemotherapy likely to reduce my risk of breast cancer returning?
2. If chemotherapy is recommended, which chemotherapy regimen is most appropriate for my tumor?

Tumor size, grade, and lymph node involvement remain important, but these features do not reveal everything about how a cancer may behave.

Two people can have breast cancers that appear very similar yet respond differently to the same treatment.

This is where genomic testing may provide another layer of information.

What Are MammaPrint and BluePrint?

MammaPrint and BluePrint are genomic tests developed by Agendia.

MammaPrint examines the activity of 70 genes inside a breast cancer tumor. It provides information about the genomic risk of the cancer spreading to another part of the body.

BluePrint examines 80 genes to identify the tumor’s molecular subtype. This may provide biological information beyond what is available through standard pathology to help better understand what is driving the tumor’s growth and how it might respond to therapies.

These tumor tests are different from inherited genetic testing:

• Genomic testing studies gene activity inside the breast cancer tumor.
• Inherited genetic testing looks for variants a person was born with, such as BRCA1 or BRCA2 variants.

Both can be important, but they answer different questions.

These tests do not make the treatment decision by themselves, but they may give your doctor more information to personalize the discussion.

You can learn more about what genomic testing reveals on our page about understanding your tumor.

What Does the New Research Suggest?

Researchers have been studying whether MammaPrint and BluePrint can help identify which people with HR-positive, HER2-negative early-stage breast cancer are most likely to benefit from anthracycline chemotherapy.

Data presented at the 2025 San Antonio Breast Cancer Symposium and published in the Journal of Clinical Oncology, Precision Oncology in June of 2026 examined patients in the FLEX Study whose cancers were classified as MammaPrint High Risk and BluePrint Luminal B-Type.

Researchers evaluated two MammaPrint groups:

• High Risk 1, or H1
• High Risk 2, or H2

In the High Risk 1 group, outcomes were very similar whether patients received AC-T or TC. At three years, 95.9% of patients who received AC-T were alive without invasive breast cancer returning, compared with 95.9% of patients who received TC. This difference was not considered statistically meaningful.

Patients with High Risk 2, Luminal B-Type tumors appeared more likely to benefit when an anthracycline was included.

All patients with High Risk 2 cancer who received an anthracycline-taxane regimen were alive without invasive breast cancer returning at three years, compared with 94.8% of those who received TC. This was an absolute difference of 5.2%.

These findings suggest that tumor biology may help identify who is more likely to benefit from anthracycline chemotherapy and who may not receive enough additional benefit to justify its risks.

These findings are referenced in the 2026 NCCN Clinical Practice Guidelines in Oncology for breast cancer (Version 2.2026), which means they may be part of broader clinical discussions. Your oncologist can explain how, or whether, they apply to your situation.

Why Might Some Tumors Respond Differently?

One important takeaway is that two tumors can look very similar on a pathology report but behave differently at the molecular level.

Research suggests that tumors classified as High Risk 2 may show:

• Higher rates of tumor cell division
• More immune-related gene activity
• Lower estrogen-associated cellular activity
• Molecular features that overlap with more aggressive cancers

These characteristics may be part of why High Risk 2 tumors appear more sensitive to anthracycline-containing treatment.

Tumors classified as High Risk 1 do not appear to share the same biological features.

Think of it as opening the hood. From the outside, two cars can look the same. What is running underneath can be very different.

What Are the Limitations?

This is encouraging evidence. It is not a final rule for treatment.

The FLEX Study is a prospective, real-world registry and observational study rather than a randomized clinical trial.

The number of patients in this study with High Risk 2 cancer was small: 153 patients with a median follow-up of about 3.2 years.

However, when researchers adjusted for other clinical factors, the anthracycline benefit remained statistically significant, while other clinical and pathological variables did not predict anthracycline benefit.

These results do not mean every patient with a High Risk 2 result must receive an anthracycline. They also do not mean an anthracycline is never appropriate for someone with a High Risk 1 result.

The findings provide another piece of information that patients and oncologists can consider together.

Agendia and Learn Look Locate: Helping Patients Understand Their Options

Agendia is an important part of Learn Look Locate’s work to bring clear, personalized breast cancer education to people around the world.

Through our work with Agendia, we are helping patients understand that breast cancer treatment decisions may involve much more than tumor size, stage, or lymph node involvement.

The biology inside the tumor matters. Patients deserve to know whether genomic testing could provide information that may shape their care.

As a breast cancer survivor, I know how overwhelming it is to make life-changing decisions while learning an entirely new medical language.

This education is not about suggesting that one test or treatment is right for everyone. It is about helping patients understand what may be available and giving them the language to ask informed questions.

Patients should not simply be handed a treatment plan.

They deserve to understand why a treatment is being recommended, how much it may help, and whether genomic testing could make that recommendation more personal.

Questions to Ask Your Medical Oncologist

You do not need to know all the science to ask good questions. Bringing a few specific questions to your appointment can help you and your doctor talk through the options together.

If you have early-stage HR-positive, HER2-negative breast cancer, consider asking:

• Am I eligible for tumor genomic testing?
• Could MammaPrint and BluePrint provide useful information about my cancer?
• Is my tumor classified as High Risk 1 or High Risk 2?
• What molecular subtype did BluePrint identify?
• Is chemotherapy likely to benefit me?
• Why are you recommending AC-T rather than TC — or TC rather than AC-T?
• What is my estimated absolute benefit from adding an anthracycline?
• What are the potential short- and long-term risks?
• How will my heart function be evaluated?
• How does the FLEX research apply to my diagnosis?
• Would a second opinion be helpful?

Frequently Asked Questions

Q1. Why is doxorubicin called the Red Devil?
A: Doxorubicin, an anthracycline chemotherapy, is bright red and can cause significant side effects, which led to the nickname “Red Devil.” The name is widely used by patients, but it should not determine how someone feels about the treatment. The more important questions are why it is being recommended and how much benefit it may provide.

Q2. Does everyone with early-stage breast cancer need the Red Devil?
A: No. Some patients do not need chemotherapy at all, while others may receive a non-anthracycline regimen such as TC. Treatment depends on the breast cancer subtype, stage, clinical features, genomic biology, and the person’s overall health.

Q3. What is the difference between AC-T and TC chemotherapy?
A: AC-T includes doxorubicin, cyclophosphamide, and a taxane. TC generally includes docetaxel and cyclophosphamide but does not contain an anthracycline. Neither regimen is automatically best for every patient.

Q4. What is MammaPrint High Risk 2?
A: High Risk 2 identifies tumors with certain genomic characteristics associated with a higher risk of distant recurrence. FLEX Registry evidence suggests that people with High Risk 2 Luminal B tumors may be more likely to benefit from anthracycline chemotherapy.

Q5. Can MammaPrint tell me which chemotherapy I need?
A: MammaPrint and BluePrint may provide information that helps refine chemotherapy decisions, but they do not make the decision alone. Results must be considered with the tumor’s stage and pathology, lymph node status, overall health, and personal preferences.

Q6. Is MammaPrint the same as BRCA testing?
A: No. MammaPrint examines gene activity inside the breast cancer tumor. BRCA testing generally looks for an inherited genetic variant that can increase the risk of developing certain cancers. A person may be eligible for both because they answer different questions.

Part of the Red Devil Chemo series. See the complete guide

A Note From Cynthia

When I was diagnosed, I did not know which questions I needed to ask.

That is one of the reasons I created Learn Look Locate.

The Red Devil may be the right treatment for some people. Not for everyone.

Patients deserve to understand why it is being recommended, how much it may help, and whether genomic testing could provide more personalized information.

With education, research, and shared decision-making, we are moving closer to the right treatment for the right person.

Cynthia Jordan, Breast Cancer Survivor and Founder of Learn Look Locate

Agendia is a sponsor of Learn Look Locate. This article is educational content produced independently by Learn Look Locate and was not written by Agendia.

This content is for educational purposes and is not a substitute for medical advice. Treatment recommendations should be discussed with your oncology team based on your individual diagnosis and health history.

Sources:

• Agendia: Anthracycline Chemotherapy Benefit in HR+/HER2− Early-Stage Breast Cancer
• O’Shaughnessy J, Brufsky AM, Rahman RL, et al. Prediction of anthracycline benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer by the MammaPrint 70-gene signature for patients enrolled in the FLEX study. JCO Precision Oncology. 2026;10:e2501285. doi:10.1200/PO-25-01285.
• NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2026